Sionna Therapeutics (NASDAQ:SION) Major Shareholder Sells $10,000,000.00 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) major shareholder Tpg Gp A, Llc sold 250,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the sale, the insider directly owned 6,494,962 shares of the company’s stock, valued at $259,798,480. The trade was a 3.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Sionna Therapeutics Price Performance

SION traded up $0.22 on Monday, reaching $42.60. 148,368 shares of the company’s stock were exchanged, compared to its average volume of 298,998. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $45.00. The stock has a market cap of $1.90 billion and a PE ratio of -8.75. The stock’s fifty day moving average price is $41.20 and its 200-day moving average price is $31.56.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Institutional Investors Weigh In On Sionna Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. purchased a new position in Sionna Therapeutics in the 3rd quarter valued at approximately $30,000. BNP Paribas Financial Markets acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at $45,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Sionna Therapeutics in the fourth quarter valued at $89,000. Finally, Virtus Investment Advisers LLC acquired a new position in Sionna Therapeutics during the 2nd quarter worth $96,000.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday, January 5th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research report on Monday, December 1st. Finally, BTIG Research restated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.43.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.